药品作为一种特殊商品,利益与风险并存,在治疗疾病的同时也会导致药品不良反应。近百年来,世界性药害事件频频发生,已经引起了世界各国医疗工作者、药品生产者、消费者的密切关注,也使各国药品监管部门意识到加强药品安全性监测的重要性及建立药品不良反应损害救济制度的必要性。
本文通过比较分析欧盟、美国、日本以及我国台湾地区关于药品不良反应损害的判例和立法情况,结合侵权行为法基本理论和最新的发展方向,提出构建和完善我国药品不良反应损害救济制度的构想;重点分析并提出了药品不良反应损害救济制度的救济模式、立法体系、机构设置、救济对象、救济范围、给付条件、资金来源、支付比例等,为我国药品不良反应损害救济制度的建立提供参考依据。
<<As a special commodity,the drug provides both the benefit and the risk. It cures diseases and may bring adverse drug reaction (ADR). In the past one hundred years,worldwide adverse drug events happened frequently,which aroused close attention from medical personnel,drug manufacturers and consumers,and made drug regulation authorities aware of the importance of strengthening drug safety monitoring and the necessity to establish ADR relief mechanism.
This paper is to compare and analyze the cases and regulations of adverse drug damage in EU,USA,Japan and Taiwan;and according to the basic theory and future development of tort law,put forward a plan to construct and improve ADR relief mechanism in China;and mainly analyze and propose the relief pattern,legislation system,organization setting,relief object,relief scope,payment qualification,capital source,and payment proportion of ADR injury relief mechanism,providing an effective reference to establish ADR injury relief mechanism in China.
<<